Longitudinal Microperimetric Changes of Macular Sensitivity in Stargardt Disease After 12 Months

Authors:

Abstract
Stargardt disease type 1 (STGD1) is caused by pathogenic mutations in the ABCA4 gene (OMIM 601691) and leads to atrophic-appearing macular lesions and variable loss of best-corrected visual acuity (BCVA),1 often from 20/20 to 20/400 or worse.2 BCVA remains the most commonly used functional end point in clinical trials for various retinal diseases. However, the Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) study recently showed that BCVA is unlikely to be a sensitive outcome measure in STGD1 except in certain subgroups because of the slow rate of BCVA loss.2,3 Conventional perimetry may not be appropriate for conditions that affect the fovea and lead to eccentric fixation.4 Fundus-controlled (micro)perimetry allows precise functional analysis of the macula by displaying stimuli in preplanned retinal areas.5 The MP-1 microperimeter is reliable for testing of macular function in STGD1.6 Point-by-point retest limits were determined to be ±4.2 dB and independent of the magnitude of overall measured sensitivity.6 We assessed longitudinal changes in microperimetric sensitivity during a 12-month period and their association with various parameters in patients with STGD1.

This publication has 28 references indexed in Scilit: